In order to evaluate the efficacy of combined use of MNPs and EMFs in the transfer of cells with antitumor activity for cancer treatment, we chose a murine syngeneic tumour model, where the implanted EG7-OVA tumour cells express an OVA antigen that can be specifically recognised by OT-I CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.